Oxipit

What is Oxipit?

Oxipit is a radiology AI company whose flagship ChestLink identifies normal chest X-rays autonomously. The vendor claims 99.9% precision on normal studies and says it can automate up to 40% of cases. Sectra acquired Oxipit in March 2026.

Key capabilities of Oxipit

• ChestLink: autonomous reporting of normal chest X-rays
• CXR Suite: chest X-ray analysis
• CT Suite: chest CT imaging, new
• MSK Suite: musculoskeletal imaging, new
• CT Eye and MSK Eye: CE-marked CT and musculoskeletal solutions
• PACS integration: fits into existing PACS workflows

How Oxipit works

ChestLink reads chest X-rays inside the PACS workflow, auto-reports studies it classifies as normal, and leaves abnormal or uncertain studies for radiologists. The vendor says autonomous operation is CE marked in Europe and not available for autonomous use in the United States.

Who uses Oxipit?

Hospitals and imaging providers in Europe that want to reduce routine reporting load. The vendor cites recent selections by Diagnostikum Group in Austria and German Medical Institute.

Oxipit pricing

Oxipit does not publish prices. Implementations go through the vendor and partner networks such as DeepC.

Oxipit alternatives

Kheiron Medical and iCAD focus on breast imaging AI, HeartFlow analyzes coronary CT, and Corti and DeepScribe address clinical conversations rather than imaging.